No­vo Nordisk oral semaglu­tide tri­al shows re­duc­tion in blood sug­ar, plus weight loss

No­vo Nordisk is test­ing high­er lev­els of its oral ver­sion of its GLP-1, semaglu­tide, and its type 2 di­a­betes tri­al re­sults re­leased to­day show re­duc­tions in blood sug­ar as well as weight loss.

In the Phase II­Ib tri­al, No­vo com­pared its oral semaglu­tide in 25 mg and 50 mg dos­es with the 14 mg ver­sion that’s cur­rent­ly the max­i­mum ap­proved dose. The tri­al looked at how the dos­es com­pared when added to a sta­ble dose of one to three oral an­tidi­a­bet­ic med­i­cines in peo­ple with type 2 di­a­betes who were in need of an in­ten­si­fied treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER